The impact of percutaneous vagus nerve stimulation on the postoperative recovery quality of patients undergoing cardiac surgery: A prospective randomized controlled trial

INTERVENTION: The taVNS group:Transcutaneous auricular vagus nerve stimulation(taVNS);The sham taVNS group:Pseudo‐transcutaneous auricular vagus nerve stimulation; CONDITION: Coronary heart disease PRIMARY OUTCOME: QoR‐15 Recovery Quality Score; SECONDARY OUTCOME: Postoperative resting and active pain (VAS) scores;Neutrophil/lymphocyte ratio (NLR);Ainsworth Insomnia Scale (AIS) score;Serum creatine kinase isoenzyme, troponin I;Postoperative mechanical ventilation duration;Systemic Immune Inflammation Inde X(SII);Quality of Recovery Scores of QoR‐15;Delirium score;The incidence rates of death within 28 days after surgery, stroke, reoperation, and adverse events related to taVNS;The incidence of nausea and vomiting;The occurrence of adverse reactions related to electrical stimulation, such as ear pain, headache, dizziness, redness and swelling of the skin, or skin damage.;Blood test results: Liver and kidney function parameters (ALT, AST, creatinine, glomerular filtration rate); INCLUSION CRITERIA: 1.Age range: 18 ‐ 80 years old; 2.ASA ? III; 3.BMI 18.5 28; 4.Undergoing open heart valve surgery or coronary artery bypass grafting under the assistance of elective extracorporeal circulation; 5.Voluntary signing of the informed consent form;